Corporate Member Celgene - NEW Indication

Corporate Member Celgene - NEW Indication

Revlimid (lenalidomide)
April, 2017

REVLIMID is indicated as maintenance therapy in patients with multiple myeloma (MM) following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members